AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • October 26th, 2018 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Washington
Contract Type FiledOctober 26th, 2018 Company Industry JurisdictionTHIS AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 25 day of October, 2018, by and between SEATTLE GENETICS, INC., a Delaware corporation (“Company”) and Roger D. Dansey, M.D. (“Executive”).
SEATTLE GENETICS, INC. AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT2007 Equity Incentive Plan Stock Option Agreement • October 26th, 2018 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledOctober 26th, 2018 Company Industry JurisdictionTHIS STOCK OPTION AGREEMENT (the "Agreement") dated %%OPTION_DATE,'MM/DD/YYYY'%-% ("Grant Date") between Seattle Genetics, Inc., a Delaware corporation (the "Company"), and %%FIRST_NAME%-% %%MIDDLE_NAME%-% %%LAST_NAME%-% ("Optionee"), is entered into as follows:
SEATTLE GENETICS, INC. AMENDED AND RESTATED 2007 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT FOR NON-US PARTICIPANTSEquity Incentive Plan Stock Option Agreement • October 26th, 2018 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledOctober 26th, 2018 Company Industry JurisdictionTHIS STOCK OPTION AGREEMENT (the "Agreement") dated %%OPTION_DATE,'MM/DD/YYYY'%-% ("Grant Date") between Seattle Genetics, Inc., a Delaware corporation (the "Company"), and %%FIRST_NAME%-% %%MIDDLE_NAME%-% %%LAST_NAME%-% ("Optionee"), is entered into as follows:
AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • October 26th, 2018 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Washington
Contract Type FiledOctober 26th, 2018 Company Industry JurisdictionTHIS AMENDED & RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 25 day of October, 2018, by and between SEATTLE GENETICS, INC., a Delaware corporation (“Company”) and Clay B. Siegall (“Executive”).